Hsbc Holdings PLC Invests $2.27 Million in Lantheus Holdings, Inc. $LNTH

Key Points

• HSBC Holdings purchased 20,539 shares of Lantheus Holdings in the second quarter, valued at approximately $2.27 million. Institutional investors collectively own 99.06% of the company.
• Lantheus reported quarterly earnings of $1.55 per share, exceeding estimates of $1.30, while revenue of $388.18 million also topped expectations and increased 2.7% year over year.
• Analysts maintain a consensus “Hold” rating, with an average price target of $108.11. Shares opened at $100.25, near their 52-week high of $111.86.

Hsbc Holdings PLC purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 20,539 shares of the medical equipment provider's stock, valued at approximately $2,273,000.

Several other hedge funds also recently added to or reduced their stakes in the company. Farallon Capital Management LLC raised its holdings in shares of Lantheus by 56.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider's stock worth $361,199,000 after buying an additional 1,950,252 shares during the period. Jupiter Topco LLC purchased a new position in Lantheus during the 2nd quarter valued at $575,628,000. Reinhart Partners LLC. grew its position in Lantheus by 2.2% in the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider's stock valued at $177,437,000 after acquiring an additional 34,501 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Lantheus by 3.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider's stock valued at $94,202,000 after acquiring an additional 44,374 shares during the last quarter. Finally, Carmignac Gestion lifted its position in shares of Lantheus by 18.4% during the first quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider's stock worth $100,729,000 after purchasing an additional 206,000 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on LNTH. Citizens Jmp reiterated a "market outperform" rating and set a $115.00 price objective on shares of Lantheus in a report on Monday, June 29th. Weiss Ratings raised shares of Lantheus from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, August 27th. Brookline Capital Markets lowered Lantheus from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 28th. Mizuho reduced their price objective on Lantheus from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Wednesday, July 29th. Finally, Truist Financial lowered Lantheus from a "buy" rating to a "hold" rating and decreased their target price for the company from $125.00 to $102.50 in a research report on Monday, August 3rd. Four analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $108.11.

Lantheus Trading Down 0.1%

Shares of NASDAQ:LNTH opened at $100.25 on Friday. The business's 50-day moving average is $102.18 and its 200 day moving average is $93.74. Lantheus Holdings, Inc. has a 1 year low of $49.67 and a 1 year high of $111.86. The firm has a market capitalization of $6.54 billion, a P/E ratio of 24.22 and a beta of -0.03. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The business had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. During the same quarter last year, the company earned $1.57 earnings per share. The company's quarterly revenue was up 2.7% on a year-over-year basis. On average, research analysts predict that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc NASDAQ: LNTH is a healthcare company that develops, manufactures and commercializes diagnostic imaging agents and radiopharmaceuticals. Its products are designed to help physicians detect, characterize and monitor disease, with applications in cardiology, oncology and other areas of medicine.

The company's principal products include DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound images, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and assess prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.